91 related articles for article (PubMed ID: 23481520)
1. Diabetes mellitus in women can be RUTHless: lessons from the Raloxifene Use for The Heart (RUTH) Trial.
Budoff MJ
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):137-8. PubMed ID: 23481520
[No Abstract] [Full Text] [Related]
2. Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.
Daniels LB; Grady D; Mosca L; Collins P; Mitlak BH; Amewou-Atisso MG; Wenger NK; Barrett-Connor E;
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):164-70. PubMed ID: 23481531
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene vs tamoxifen.
Goldstein SR
JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
[No Abstract] [Full Text] [Related]
4. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
[TBL] [Abstract][Full Text] [Related]
5. Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients?
Cirpan T; Akercan F; Itil IM; Gundem G; Bilgen I; Yucebilgin MS
Eur J Gynaecol Oncol; 2006; 27(2):177-8. PubMed ID: 16620065
[TBL] [Abstract][Full Text] [Related]
6. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
Hamaya E; Sowa H
Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238
[No Abstract] [Full Text] [Related]
7. Carotid artery intima-media thickness after raloxifene treatment.
Mack WJ; Dhungana B; Dowsett SA; Keech CA; Feng M; Li Y; Hodis HN
J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
10. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
11. Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis.
Su FM; Chen YC; Cheng TT; Lin WC; Lui CC
BMC Musculoskelet Disord; 2015 Aug; 16():209. PubMed ID: 26286481
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
Ohta H; Hamaya E; Taketsuna M; Sowa H
Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
[TBL] [Abstract][Full Text] [Related]
13. In reply.
Urushihara H
Menopause; 2014 Jan; 21(1):110. PubMed ID: 24326283
[No Abstract] [Full Text] [Related]
14. Hypocalcemia induced by raloxifene.
Vu TD; Varadarajan S; Seeman E; Jerums G; MacIsaac RJ
Curr Drug Saf; 2012 Apr; 7(2):176-8. PubMed ID: 22873502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis.
Lu HF; Chou PH; Lin GH; Chou WH; Wang ST; Adikusuma W; Mugiyanto E; Hung KS; Chang WC
Dis Markers; 2020; 2020():8855423. PubMed ID: 32934756
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Sahebari M; Sarafraz Yazdi M; Mehrnaz Aghili S; Esmaily H; Saeidi S; Salari M
Curr Rheumatol Rev; 2023; 19(1):93-101. PubMed ID: 35585813
[TBL] [Abstract][Full Text] [Related]
17. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.
Uusi-Rasi K; Beck TJ; Semanick LM; Daphtary MM; Crans GG; Desaiah D; Harper KD
Osteoporos Int; 2006; 17(4):575-86. PubMed ID: 16392026
[TBL] [Abstract][Full Text] [Related]
18. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
Li L; Roddam A; Gitlin M; Taylor A; Shepherd S; Shearer A; Jick S
Menopause; 2012 Jan; 19(1):33-40. PubMed ID: 21926926
[TBL] [Abstract][Full Text] [Related]
19. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.
Seeman E; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):313-6. PubMed ID: 16217588
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
